Safety and immunogenicity of Env 2-3, a human immunodeficiency virus type 1 candidate vaccine, in combination with a novel adjuvant, MTP-PE/MF59

AIDS Research and Human Retroviruses

Volumn 12, Issue 8, 1996, Pages 683-693

  Keefer, Michael C ^a,h   Graham, Barney S ^b   McElrath, M Juliana ^c   Matthews, Thomas J ^d   Stablein, Donald M ^e   Corey, Lawrence ^c   Wright, Peter F ^b   Lawrence, Dale ^f   Fast, Patricia E ^f   Weinhold, Kent ^d   Hsieh, Ray Hahn ^e   Chernoff, David ^g   Dekker, Corry ^g   Dolin, Raphael ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e EMMES CORPORATION   (United States)

^f NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^g NOVARTIS PHARMA AG   (Switzerland)

^h UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOLOGICAL ADJUVANT; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; NEUTRALIZING ANTIBODY;

ADULT; ANTIBODY RESPONSE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG FORMULATION; DRUG SAFETY; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; INJECTION PAIN; INTRAMUSCULAR DRUG ADMINISTRATION; MALAISE; MALE; MYALGIA; NAUSEA; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE ACTIVATION; VACCINE PRODUCTION;

EID: 9244255773     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.1996.12.683     Document Type: Article

References (36)

1. Walker MC and Fast P: Clinical trials of candidate AIDS vaccines. AIDS 1994;8(Suppl. 1):S213-S236.
2. Kurth R, Binninger D, Emmen J, et al.: The quest for an AIDS vaccine: The state of the art and current challenges. AIDS Res Hum Retroviruses 1991;7(5):425-433.
3. Bolognesi DP: Human immunodeficiency virus vaccines. Adv Virus Res 1993;42:103-148.
4. Berzofsky JA: Approaches and issues in the development of vaccines against HIV. J AIDS 1991;4(5):451-459.
5. Dolin R, Graham BS, Greenberg SB, et al.: The safety and immunogenicity of a human immunodeficiency virus type-1 (HIV-1) recombinant gp160 candidate vaccine in humans. Ann Intern Med 1991;114:119-127.
6. Belshe R, Clements ML, Dolin R, et al.: Safety and immunogenicity of a fully glycosylated recombinant gp160 HIV-1 vaccine in low risk volunteers. J Infect Dis 1993;168:1387-1395.
7. Schwartz D, Gorse G, Clements ML, et al.: Induction of HIV-1 neutralizing and syncytium-inhibiting antibodies in seronegative recipients of HIV-1 IIIB rgp120 subunit vaccines. Lancet 1993;342:69-73.
8. Belshe RB, Graham BS, Keefer MC, et al.: Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. JAMA 1994;272:475-480.
9. Keefer MC, Graham BS, Belshe RB, et al.: Studies of high doses of a human immunodeficiency virus type 1 recombinant glycoprotein 160 candidate vaccine in HIV type 1-seronegative humans. AIDS Res Hum Retroviruses 1994;10:1713-1723.
10. SF-2 rgp 120 in healthy adult volunteers. (Submitted.)
11. MN V3 branched peptide vaccine. J Infect Dis 1996;173:330-339.
12. Steimer KS, Van Nest G, Dina D, et al.: Genetically engineered human immunodeficiency envelope glycoprotein gp120 produced in yeast is the target of neutralizing antibodies. In: Vaccines 87 (Channock RM, et al., eds.). Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1987, pp. 236-241.
13. Steimer KS, Van Nest G, Haigwood NL, et al.: Recombinant Env and Gag polypeptides in characterizing HIV-1 neutralizing antibodies. In: Vaccines 88 (Ginsberg H, ed.). Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1988, pp. 347-356.
14. Haigwood NL, Nara PL, Brooks E, et al.: Native but not denatured recombinant human immunodeficiency virus type 1 gp120 generates broad-spectrum neutralizing antibodies in baboons. J Virol 1992;66:172-182.
15. Schultz AM and Hu SL: Primate models for HIV vaccines. AIDS 1993;7(Suppl. 1):S161-S170.
16. Van Nest GA, Steimer KS, Haigwood NL, et al.: Advanced adjuvant formulation for use with recombinant vaccines. In: Vaccines 92 (Brown F, Chanock R, Ginsberg HS, and Lerner R, eds.). Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1992, pp. 57-62.
17. Wintsch J, Chaignot J, Brain DG, et al.: Safety and immunogenicity of a genetically engineered human immunodeficiency virus vaccine. J Infect Dis 1991;163:219-225.
18. Abrignani S, Montagna D, Jeannet M, et al.: Priming of CD4+ T cells specific for conserved regions of human immunodeficiency virus glycoprotein gp120 in humans immunized with a recombinant envelope protein. Proc Natl Acad Sci USA 1990;87:6136-6140.
19. Keitel W, Couch R, Bond N, et al.: Pilot evaluation of influenza virus vaccine (IVV) combined with adjuvant. Vaccine 1993;11:909-913.
20. Keefer MC, Bonnez W, Roberts NJ Jr, et al.: Human immunodeficiency virus (HIV-1) gp160-specific lymphocyte proliferative responses of mononuclear leukocytes from HIV-1 recombinant gp160 vaccine recipients. J Infect Dis 1991;163:448-453.
21. Abbott Laboratories, Diagnostics Division: Abbott HIV EIA. Abbott Laboratories, North Chicago, Illinois, 1987.
22. Graham BS, Matthews TJ, Belshe RB, et al.: Augmentation of human immunodeficiency virus type-1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. J Infect Dis 1993;167:533-537.
23. Skinner MA, Langlois AJ, McDanal CB, et al.: Neutralizing antibodies to an immunodominant envelope sequence do not prevent gpI20 binding to CD4. J Virol 1988;62:4195-4200.
24. + cytotoxic activity after receipt of envelope vaccines. J Infect Dis 1993;168:306-313.
25. McElrath MJ, Keefer MC, Greenberg P, et al.: Evaluation of a nonglycosylated yeast-derived envelope vaccine on HIV-1 specific immunity in a randomized, blinded, controlled HIV-1 seropositive trial. In: Abstracts of the IXth International Conference on AIDS/IVth STD World Congress. Berlin, Germany, June 1993. [Abstract PO-A28-0670]
26. VanCott TC, Polonis VR, Loomis LD, Michael NL, Nara PL, and Birx DL: Differential role of V3-spccific antibodies in neutralization assays involving primary and laboratory-adapted isolates of HIV type 1. AIDS Res Hum Retroviruses 1995;11:1379-1391.
27. Hanson CV: Measuring vaccine-induced HIV neutralization: Report of a workshop. AIDS Res Hum Retroviruses 1994;10: 631-633.
28. Mascola JR, Snyder SW, Weislow OS, et al. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. J Infect Dis 1996;173:340-348.
29. Bolognesi D: HIV Vaccines. In: AIDS Updates (DeVita VTR, Hellman S, and Rosenberg SA, eds.). J. B. Lippincott, Philadelphia, Pennsylvania, 1994, pp. 1-8.
30. Gorse GJ, Belshe RB, Newman FK, et al.: Lymphocyte proliferative responses following immunization with human immunodeficiency virus recombinant gp160. Vaccine 1992;10:383-388.
31. Orentas RJ, Hildreth JEK, and Obah E: Induction of CD4+ cytolytic T-cells specific for HIV-infected cells by a gp160 subunit vaccine. Science 1990;248:1234-1237.
32. Stanhope PE, Liu AY, Parlat W, et al.: An HIV-1 envelope protein vaccine elicits a functionally complex human CD4+ T cell response that includes cytolytic T lymphocytes. J Immunol 1993;150:4672-4686.
33. Stanhope PE, Clements ML, and Siliciano RF: Human CD4+ cytoloytic T lymphocyte responses to a human immunodeficiency virus type 1 gp160 subunit vaccine. J Infect Dis 1993;168:92-100.
34. Gorse GJ, Patel GB, Newman FK, et al.: Recombinant gp160 vaccination schedule and MHC HLA type as factors influencing cellular immune responses to HIV-1 envelope glycoprotein. Vaccine 1995;13:1170-1179.
35. Hammond SA, Bollinger RC, Stanhope PE, et al.: Comparative clonal analysis of human immunodeficiency virus type 1 (HIV-1)-specific CD4+ and CD8+ cytolytic T lymphocytes isolated from seronegative humans immunized with candidate HIV-1 vaccines. J Exp Med 1992;176:1531-1542.
36. McElrath MJ, Hoffman M, Klucking S, et al.: HIV-infected macrophages as efficient stimulator cells for detection of cytotoxic T cell responses to HIV-1 in seronegative and seropositive vaccine recipients. AIDS Res Hum Retroviruses 1994;10:541-549.